In 2020 PHARMACEUTICALS-BASE published article about P-GLYCOPROTEIN; RESIDUES in [Kreutzer, David; Hilgeroth, Andreas] Martin Luther Univ Halle Wittenberg, Inst Pharm, Res Grp Drug Dev, D-06108 Halle, saale, Germany; [Ritter, Christoph A.] Ernst Moritz Arndt Univ Greifswald, Inst Pharm, Dept Clin Pharm, D-17489 Greifswald, Germany in 2020, Cited 27. The Name is Ethyl nicotinate. Through research, I have a further understanding and discovery of 614-18-6. Name: Ethyl nicotinate
Cancer is a strong global burden with increasing numbers of diseases and ongoing anticancer drug resistance. The number of structurally novel anticancer drugs is strongly limited. They cause high costs for the social health systems. Most critical so-called multidrug resistances (MDR) are caused by transmembrane efflux pumps that transport drugs with various structures out of the cancer cells. Multidrug resistance proteins (MRPs) type 1 and 2 are found overexpressed in various kinds of cancer. There is a strong need for inhibitors of those efflux pumps. We developed novel nonsymmetrical 1,4-dihydropyridines as novel inhibitors of cancer relevant MRP types 1 and 2. The structure-dependent activities of the differently substituted derivatives were evaluated in cellular assays of respective cancer cells and are discussed. Promising candidates were identified. One candidate was demonstrated to resensitize a cisplatin resistant cancer cell line and thus to overcome the anticancer drug resistance.
Name: Ethyl nicotinate. About Ethyl nicotinate, If you have any questions, you can contact Kreutzer, D; Ritter, CA; Hilgeroth, A or concate me.
Reference:
Pyridine – Wikipedia,
,Pyridine | C5H5N – PubChem